Latest news with #IvanTornos
Yahoo
a day ago
- Business
- Yahoo
Zimmer (ZBH) Builds Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside
Zimmer Biomet Holdings Inc. (NYSE:ZBH) is one of the best defensive stocks to invest in according to analysts. With a decline of around 14%, Zimmer's YTD share price performance has been weak. Its management is focussing on reinvigorating growth, and in a bid to expand its robotics platform and its portfolio of navigation and enabling technologies, the company had announced the acquisition of Monogram Technologies Inc. (NASDAQ:MGRM) on July 14 for an enterprise value of $168 million. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. Monogram is an orthopaedic robotics company, and Ivan Tornos, Chairman and CEO of Zimmer Biomet, expects the deal to boost his company's offerings with semi- and fully autonomous robotic technologies. On the prospects of the integration, he stated: 'Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopaedic surgery.' Analyst opinions over the deal have been mixed. While analysts from RBC Capital and BTIG reaffirmed their positive view, the agreement has not changed the opinion of BofA analyst Travis Steed, who reiterated a Hold rating and a $110 price target following the deal announcement. He noted that while the acquisition strengthens ZBH's position in the semi-autonomous robotics market, the financial benefits will be modest in the near term. As per the company management, the transaction will be funded through cash and available debt and is expected to be EPS neutral through 2027 and accretive thereafter. However, Steed believes the company's already strong margins limit further EPS upside, and while the move broadens ZBH's competitive edge, material revenue contributions are not expected until 2027. Zimmer Biomet Holdings Inc. (NYSE:ZBH) is a global medical technology company that designs, develops, manufactures, and markets orthopaedic products, including implants, digital and robotic solutions. While we acknowledge the potential of ZBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
5 days ago
- Business
- Yahoo
Zimmer Biomet raises annual profit forecast on strong demand for medical devices
(Reuters) -Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants. Medical device makers have benefited from a surge in demand as more people, particularly older Americans, sought health care services and surgical procedures. The demographic shift toward an aging population continues to fuel robust procedure volumes across orthopedic specialties. Zimmer expects 2025 adjusted profit per share in the range of $8.10 to $8.30, up from its prior view of $7.90 to $8.10 per share. Analysts were expecting $7.97 per share, according to data compiled by LSEG. "Our robust new product cycle drove significant acceleration in our U.S. hips and knees portfolios and continued strong growth in our global S.E.T. (sports medicine, extremities, and trauma) business," CEO Ivan Tornos said. The company attributed its performance to early customer adoption of its new product portfolio, including advancements in surgical robotics. Combined sales at Zimmer's hips and knees units came in at $1.36 billion during the quarter ended June 30, compared with $1.31 billion a year ago. Sales at its unit that sells sports medicine and trauma care products climbed 17.3% to $550.6 million, while analysts estimated $534 million. It posted an adjusted profit of $2.07 per share, topping estimates of $1.98 per share. Its second-quarter revenue came in at $2.08 billion, also above expectations of $2.05 billion. Zimmer said it expects 2025 revenue growth of 6.7% to 7.7%, from its prior 5.7% to 8.2% forecast.
Reuters
5 days ago
- Business
- Reuters
Zimmer Biomet raises annual profit forecast on strong demand for medical devices
Aug 7 (Reuters) - Zimmer Biomet Holdings (ZBH.N), opens new tab raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants. Medical device makers have benefited from a surge in demand as more people, particularly older Americans, sought health care services and surgical procedures. The demographic shift toward an aging population continues to fuel robust procedure volumes across orthopedic specialties. Zimmer expects 2025 adjusted profit per share in the range of $8.10 to $8.30, up from its prior view of $7.90 to $8.10 per share. Analysts were expecting $7.97 per share, according to data compiled by LSEG. "Our robust new product cycle drove significant acceleration in our U.S. hips and knees portfolios and continued strong growth in our global S.E.T. (sports medicine, extremities, and trauma) business," CEO Ivan Tornos said. The company attributed its performance to early customer adoption of its new product portfolio, including advancements in surgical robotics. Combined sales at Zimmer's hips and knees units came in at $1.36 billion during the quarter ended June 30, compared with $1.31 billion a year ago. Sales at its unit that sells sports medicine and trauma care products climbed 17.3% to $550.6 million, while analysts estimated $534 million. It posted an adjusted profit of $2.07 per share, topping estimates of $1.98 per share. Its second-quarter revenue came in at $2.08 billion, also above expectations of $2.05 billion. Zimmer said it expects 2025 revenue growth of 6.7% to 7.7%, from its prior 5.7% to 8.2% forecast.
Yahoo
15-07-2025
- Business
- Yahoo
Zimmer to buy robotics firm Monogram for about $177M
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet said Monday that it plans to buy Monogram Technologies, an orthopedics company with a robot for knee replacement procedures, for about $177 million. Monogram's mBôS robot received Food and Drug Administration clearance in March for total knee replacement surgeries. The system uses CT scans and AI navigation for orthopedic procedures. Monogram's robot will be sold with Zimmer implants in early 2027, the companies said in the announcement. They expect the merger to close later this year, if approved by regulators and Monogram's shareholders. The Monogram acquisition is expected to give surgeons more options and grow Zimmer's orthopedic robotics portfolio. Currently, Zimmer sells its Rosa robot, which is designed for imageless surgeries, or can use 2D X-rays to help with surgical planning. Monogram's robot, by contrast, uses CT imaging and offers predictive navigation. Monogram is working on a fully autonomous version of the robot and securing additional applications beyond total knee surgery. Zimmer CEO Ivan Tornos said the acquisition will give Zimmer 'the most comprehensive and flexible technology ecosystem' to support surgeons' varying preferences, and the combined firm will have 'the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery." Zimmer will buy all of Monogram's outstanding shares for $4.04 per share in cash upfront, for a total equity value of about $177 million and an enterprise value of approximately $168 million. Monogram's shareholders will also be able to receive up to $12.37 per share in common stock if certain development, regulatory and revenue milestones are met through 2030. Both companies' boards have approved the deal. Monogram's shares increased by more than 75% to $5.78 in Monday morning trading. Zimmer has been working to grow its robotics business through new indications and acquisitions. Last year, Zimmer received 510(k) clearance for its Rosa shoulder system and partnered with Think Surgical, which makes a wireless handheld robotic knee surgery device. Zimmer expects the Monogram purchase will contribute to revenue growth starting in 2027 and be neutral to earnings per share in the first three years. The deal is expected to be accretive to earnings starting in 2028. The Monogram deal follows Zimmer's proposal to acquire Paragon 28 for $1.1 billion, which closed in April. Recommended Reading Monogram robot wins FDA OK; Vicarious hit by supplier woes Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees
ROSEMONT, Ill., May 29, 2025 /PRNewswire/ -- The Orthopaedic Research and Education Foundation (OREF), the leading private nonprofit organization funding musculoskeletal (MSK) research across all orthopaedic sub-specialties, is pleased to announce that Ivan Tornos, Chairman, President and CEO of orthopaedic medical device company Zimmer Biomet has joined its Board of Trustees. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics. Prior to his appointment as President and Chief Executive Officer in 2023, he held the positions of Group President, Global Businesses and the Americas, and Chief Operating Officer with responsibility for overseeing all global businesses at Zimmer Biomet. He was elected Chairman of the Board of Directors of Zimmer Biomet, a global leader in musculoskeletal health, in May of 2025. OREF Board President, Joshua J. Jacobs, MD, stated, "On behalf of the entire board, I am delighted to welcome Ivan to OREF. Our two organizations have a long history of collaboration and a shared commitment to improving patient care and outcomes. Ivan's presence on the OREF board will bring heightened visibility to our mission and to the need for more research funding. His service to OREF and the financial support of Zimmer Biomet underscore his commitment to improving the health of our communities here in the U.S. and throughout the world." "I am thrilled to be joining the OREF board. Now more than ever, it's important we move with a sense of urgency and deep purpose to ensure that musculoskeletal research advances at a much faster pace and delivers even bolder solutions. There are countless patients currently waiting on the sidelines who could benefit from the meaningful work that we will do together, and I'm committed to doing all I can to reduce the current gaps in this area," said Ivan Tornos. The growing burden of MSK conditions in the United States is well documented with MSK-related diseases and injuries affecting more than half of the adult population and imposing an estimated economic burden of $980 billion annually.1 Despite the outsized impact of MSK diseases on quality of life and the U.S. economy, funding for MSK conditions is disproportionately low when comparing the physical and economic burden of various diseases. OREF is a leading voice in advocating for increased MSK research funding and strongly believes that the nation's healthcare will not improve unless and until MSK research funding becomes a national priority. OREF grantees' success in securing additional funding from the NIH and other government entities is unparalleled within the MSK research community. Research published in JBJS demonstrates that OREF grant recipients are more likely to receive subsequent NIH funding compared to other applicants (23.5 percent vs. 20.6 percent), with Career Development Grant recipients achieving a 48.4 percent success rate.2 Given the limited availability of MSK research funds, investing in a reputable independent source with a proven return on investment is essential. OREF's collaboration with more than 60 MSK-related organizations is a key factor in its success in funding significant and impactful research that improves clinical practice and patient outcomes. About OREF An independent 501(c)3 nonprofit, OREF strives to improve clinical care and patient outcomes by advancing innovative research, developing new investigators, and uniting the orthopaedic community in promoting musculoskeletal health. The Foundation raises funds to support research on diseases and injuries of bones, nerves, muscles, and tendons and to enhance clinical care leading to improved health, increased activity, and a better quality of life for patients. For more information, visit or follow OREF on X and LinkedIn. 1United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS), Third Edition, 2014. Rosemont, IL. Available at 2Li, Alan K. BS1,a; Kendal, Joseph K. MD, MSc2; Hamad, Christopher D. MD2; Peterson, Nicholas V. MD2; Asachi, Parsa BA1; Taylor, Jeremiah M. BS1; Le, Michael M. MD1; Lloyd, Trevor S. BS1; Wessel, Lauren E. MD2; Bernthal, Nicholas M. MD2. Identifying Predictors of Successful Conversion from OREF Grants to Extramural Federal Funding Among Orthopaedic Surgeons. The Journal of Bone and Joint Surgery 107(1):p 96-103, January 1, 2025. DOI: 10.2106/JBJS.24.0064 View original content to download multimedia: SOURCE Orthopaedic Research and Education Foundation
